Tiotropium
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
A long-acting muscarinic antagonist (LAMA/long-acting anticholinergic) that is a first-line maintenance bronchodilator for COPD and an add-on controller for moderate-to-severe asthma. Provides sustained 24-hour bronchodilation with once-daily dosing. In COPD, tiotropium reduces exacerbations, improves lung function, quality of life, and exercise tolerance. In asthma, it is used as add-on therapy when ICS/LABA combinations are insufficient.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
A long-acting muscarinic antagonist (LAMA/long-acting anticholinergic) that is a first-line maintenance bronchodilator for COPD and an add-on controller for moderate-to-severe asthma. NutriStack rates the supporting evidence as strong. Common adult dosing is HandiHaler: 18 mcg (one capsule) inhaled once daily; Respimat: 2.5 mcg (2 puffs) once daily for COPD, 1.25 mcg (2 puffs) once daily for asthma (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: first-line maintenance bronchodilator for copd, reduces copd exacerbation frequency, improves fev1 and exercise tolerance in copd. 10 sources indexed (2014–2021), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Competitively and reversibly blocks muscarinic M3 receptors on airway smooth muscle and submucosal glands. Acetylcholine released from parasympathetic vagal nerve endings normally activates M3 receptors, causing bronchoconstriction and mucus secretion. Tiotropium's very slow dissociation from M3 receptors (kinetic selectivity, off-rate half-life of ~35 hours from M3 vs ~4 hours from M2) provides prolonged bronchodilation. This M3 selectivity avoids blocking presynaptic M2 autoreceptors, which would paradoxically increase acetylcholine release.
Dosing & protocol.
Delivered by inhalation. Oral bioavailability is extremely low (2-3%) due to quaternary ammonium structure. Systemic effects are minimal. Peak bronchodilation at 1-3 hours, duration >24 hours. Do not swallow capsules, they are for inhalation via HandiHaler device only.
Full safety detail.
Side effects
- Dry mouth (most common anticholinergic effect)
- Constipation
- Urinary retention
- Pharyngitis and upper respiratory tract infection
- Sinusitis
- Blurred vision (if sprayed into eyes)
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
5- 1Tiotropium in the management of paediatric and adolescent asthma: Systematic reviewPMIDSunther M, Marchon K, Gupta A · Paediatric respiratory reviews · 2021
Sunther M, Marchon K, Gupta A. Tiotropium in the management of paediatric and adolescent asthma: Systematic review. Paediatric respiratory reviews. 2021
- 2[Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review]PMIDCai HD, Hou J, Lyu YN et al. · Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · 2017
Cai HD, Hou J, Lyu YN et al.. [Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2017
- 3Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysisPMIDMiravitlles M, Urrutia G, Mathioudakis AG et al. · Respiratory research · 2017
Miravitlles M, Urrutia G, Mathioudakis AG et al.. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respiratory research. 2017
- 4Tiotropium formulations and safety: a network meta-analysisPMIDCazzola M, Calzetta L, Rogliani P et al. · Therapeutic advances in drug safety · 2017
Cazzola M, Calzetta L, Rogliani P et al.. Tiotropium formulations and safety: a network meta-analysis. Therapeutic advances in drug safety. 2017
- 5Tiotropium versus placebo for inadequately controlled asthma: a meta-analysisPMIDTian JW, Chen JW, Chen R et al. · Respiratory care · 2014
Tian JW, Chen JW, Chen R et al.. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis. Respiratory care. 2014
Reference material
5- 6Tashkin DP et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT). N Engl J Med. 2008.Source linkedPMID
- 7Kerstjens HA et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012.Source linkedPMID
- 8GOLD (Global Initiative for Chronic Obstructive Lung Disease). Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2023.Source linkedPMID
- 9Kesten S, Celli B, Decramer M et al.. Tiotropium HandiHaler in the treatment of COPD: a safety review. International journal of chronic obstructive pulmonary disease. 2009Source linkedPMID
- 10Blair HA. Tiotropium/Olodaterol: A Review in COPD. Drugs. 2019Source linkedPMID
Common questions.
Quick answers about Tiotropium, drawn from the data on this page.
What is Tiotropium?
A long-acting muscarinic antagonist (LAMA/long-acting anticholinergic) that is a first-line maintenance bronchodilator for COPD and an add-on controller for moderate-to-severe asthma. Provides sustained 24-hour bronchodilation with once-daily dosing. In COPD, tiotropium reduces exacerbations, improves lung function, quality of life, and exercise tolerance. In asthma, it is used as add-on therapy when ICS/LABA combinations are insufficient.
What is Tiotropium used for?
Commonly cited benefits of Tiotropium include: First-line maintenance bronchodilator for COPD; Reduces COPD exacerbation frequency; Improves FEV1 and exercise tolerance in COPD; Add-on controller for moderate-to-severe persistent asthma; Once-daily dosing for patient convenience. NutriStack rates the overall evidence as strong.
What is a typical dose of Tiotropium?
A typical adult dose of Tiotropium is HandiHaler: 18 mcg (one capsule) inhaled once daily; Respimat: 2.5 mcg (2 puffs) once daily for COPD, 1.25 mcg (2 puffs) once daily for asthma (as prescribed by your physician). The commonly recommended form is Dry powder inhaler (HandiHaler) or soft mist inhaler (Respimat). These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Tiotropium?
Reported side effects include dry mouth (most common anticholinergic effect), constipation, urinary retention, pharyngitis and upper respiratory tract infection, sinusitis, blurred vision (if sprayed into eyes). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Tiotropium?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Tiotropium in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.